Press "Enter" to skip to content

Oxford COVID-19 vaccine human trial reveals vaccine is ‘safe, well-tolerated and immunogenic’

The initial trial data for the COVID-19 vaccine that has been developed in a joint collaboration between Oxford University and AstraZeneca has been published. Editor in Chief of UK based medical Journal ‘The Lancet’ says it is “safe, well-tolerated and immunogenic.”Taking to Twitter, Richard Horton, the editor of the science journal The Lancet, said, “The phase 1/2 Oxford COVID-19 vaccine trial is now published. The vaccine is safe, well-tolerated, and immunogenic. Congratulations to Pedro Folegatti and colleagues. These results are extremely encouraging.”

Leave your comments

%d bloggers like this: